Drug Profile
Research programme: anti-cancer mRNA therapeutics - Moderna Therapeutics
Alternative Names: mRNA 2905; mRNA-IL12-iTu-I-O; MT 004; MT-377; MT-380; MT-513Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Developer Onkaido Therapeutics
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Protein synthesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 29 Mar 2019 Pharmacodynamics data from preclinical studies in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
- 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research